Acadia Healthcare Company Valuation

Q: What is the Fair Price of ACHC * when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

ACHC * (MX$1084.05) is trading above our estimate of [[fair value]] (MX$349.63)

Is ACHC * undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of ACHC * when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: ACHC * (MX$1084.05) is trading above our estimate of fair value (MX$349.63)

Significantly Below Fair Value: ACHC * is trading above our estimate of fair value.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for ACHC *?

Other financial metrics that can be useful for relative valuation.

The above table shows the n/a ratio for ACHC *. This is calculated by dividing ACHC *'s market cap by their current preferred multiple.
What is ACHC *'s n/a Ratio?
n/a	0x
n/a	n/a
Market Cap	US$5.10b

ACHC * key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	2.3x
Enterprise Value/EBITDA	10.6x
PEG Ratio	n/a

Price to Sales Ratio vs Peers

How does ACHC *'s PS Ratio compare to its peers?

The above table shows the PS ratio for ACHC * vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PS	Estimated Growth	Market Cap
Peer Average	3.6x
MEDICA B Médica Sur. de	0.7x	5.4%	Mex$3.1b
FORTIS Fortis Healthcare	6.4x	12.7%	₹450.9b
4002 Mouwasat Medical Services	6.7x	11.4%	ر.س19.1b
RHC Ramsay Health Care	0.6x	4.4%	AU$9.8b
ACHC * Acadia Healthcare Company	1.7x	9.6%	Mex$5.1b

Price-To-Sales vs Peers: ACHC * is good value based on its Price-To-Sales Ratio (1.7x) compared to the peer average (3.6x).

Price to Earnings Ratio vs Industry

How does ACHC *'s PE Ratio compare vs other companies in the South American Healthcare Industry?

0 Companies	Price / Earnings	Estimated Growth	Market Cap
Industry Avg.	n/a	28.1%
	n/a	n/a	n/a

Fetching data

0 Companies	Price / Earnings	Estimated Growth	Market Cap
Industry Avg.	n/a	28.1%
	n/a	n/a	n/a

No more companies

Price-To-Sales vs Industry: ACHC * is expensive based on its Price-To-Sales Ratio (1.7x) compared to the South American Healthcare industry average (0.8x).

Price to Sales Ratio vs Fair Ratio

What is ACHC *'s PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

ACHC * PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio	1.7x
Fair PS Ratio	n/a

Price-To-Sales vs Fair Ratio: Insufficient data to calculate ACHC *'s Price-To-Sales Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst ACHC * forecast and predictions for the stock price in 12 month’s time.
Date	Share Price	Average 1Y Price Target	Dispersion	High	Low	1Y Actual price	Analysts
Current	Mex$1,084.05	Mex$1,747.31 +61.2%	10.1%	Mex$2,067.24	Mex$1,476.60	n/a	12
Oct ’25	Mex$1,292.50	Mex$1,747.31 +35.2%	10.1%	Mex$2,067.24	Mex$1,476.60	n/a	12
Sep ’25	n/a	Mex$1,711.14 0%	9.3%	Mex$2,011.23	Mex$1,436.60	n/a	12
Aug ’25	n/a	Mex$1,658.20 0%	11.4%	Mex$1,971.07	Mex$1,314.05	n/a	12
Jul ’25	n/a	Mex$1,644.78 0%	11.3%	Mex$1,947.77	Mex$1,298.51	n/a	12
Jun ’25	n/a	Mex$1,474.86 0%	11.3%	Mex$1,746.55	Mex$1,164.37	n/a	12
May ’25	n/a	Mex$1,577.68 0%	9.8%	Mex$1,728.35	Mex$1,152.24	n/a	13
Apr ’25	n/a	Mex$1,613.73 0%	10.1%	Mex$1,772.72	Mex$1,181.81	n/a	12
Mar ’25	n/a	Mex$1,611.81 0%	11.5%	Mex$1,790.04	Mex$1,193.36	n/a	11
Feb ’25	n/a	Mex$1,511.09 0%	11.1%	Mex$1,771.89	Mex$1,147.51	n/a	11
Jan ’25	n/a	Mex$1,518.78 0%	11.5%	Mex$1,801.01	Mex$1,166.37	n/a	11
Dec ’24	n/a	Mex$1,552.93 0%	11.5%	Mex$1,841.51	Mex$1,192.60	n/a	11
Nov ’24	n/a	Mex$1,626.46 0%	11.7%	Mex$1,895.62	Mex$1,227.64	n/a	11
Oct ’24	n/a	Mex$1,550.69 0%	11.3%	Mex$1,798.24	Mex$1,164.57	Mex$1,292.50	11
Sep ’24	n/a	Mex$1,545.07 0%	11.0%	Mex$1,787.69	Mex$1,157.74	n/a	12
Aug ’24	n/a	Mex$1,516.76 0%	11.0%	Mex$1,758.16	Mex$1,138.62	n/a	12
Jul ’24	n/a	Mex$1,613.70 0%	12.0%	Mex$1,887.89	Mex$1,132.73	n/a	12
Jun ’24	n/a	Mex$1,613.70 0%	12.0%	Mex$1,887.89	Mex$1,132.73	n/a	12
May ’24	n/a	Mex$1,613.70 0%	12.0%	Mex$1,887.89	Mex$1,132.73	n/a	12
Apr ’24	n/a	Mex$1,661.17 0%	8.8%	Mex$1,890.77	Mex$1,350.55	n/a	12
Mar ’24	n/a	Mex$1,691.11 0%	6.7%	Mex$1,900.80	Mex$1,484.44	n/a	12
Feb ’24	n/a	Mex$1,830.71 0%	6.7%	Mex$2,030.54	Mex$1,585.76	n/a	12
Jan ’24	n/a	Mex$1,873.25 0%	7.0%	Mex$2,085.07	Mex$1,628.34	n/a	12
Dec ’23	n/a	Mex$1,811.94 0%	8.0%	Mex$2,047.57	Mex$1,560.06	n/a	12
Nov ’23	n/a	Mex$1,811.20 0%	8.9%	Mex$2,070.59	Mex$1,577.59	n/a	13
Oct ’23	n/a	Mex$1,803.35 0%	8.2%	Mex$2,060.31	Mex$1,560.23	n/a	13

Analyst Forecast: Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.